

Immune Checkpoint Inhibitor Treatment for Frontline Metastatic NSCLC

The Evolving Role of Biomarkers in Guiding Decisions CME

9 SEPTEMBER 2019

PRESENTATION: 18:15 – 19:45

VENUE: FIRA DE BARCELONA, GRAN VIA, HALL 8, NORTH ACCESS | **ROOM:** HILTON HEAD (1978)

www.medscape.org/symposium/nsclc-biomarkers-registration

Medscape®
LIVE!

MODERATOR



Heather Wakelee, MD
Professor of Medicine
Stanford University
Stanford, California, United States

PANELISTS



Raffaele Califano, MD
Honorary Senior Lecturer in Cancer
Sciences
Consultant in Medical Oncology
The Christie NHS Foundation Trust
Division of Cancer Sciences
University of Manchester
Manchester, United Kingdom



Wilfried Eberhardt, MD
Department of Medical Oncology
West German Cancer Center
University Hospital Essen
Essen, NRW, Germany



Marina Chiara Garassino, MD
Chief, Medical Thoracic Oncology Unit
Medical Consultant
Medical Oncology Division
Fondazione IRCCS
Istituto Nazionale dei Tumori
Milano, Italy

 *Dinner & Refreshments
provided by Medscape*

AGENDA

18:15 – 19:45

Presentation

Welcome and Introduction

*Immune Checkpoint Inhibitor
Treatment Regimens in
Frontline Metastatic NSCLC:
Where Are We Now?*

*The Role of PD-L1 Expression
in Guiding Decisions:
Analyzing the Current
Evidence*

*The Role of Tumor
Mutational Burden (TMB)
in Guiding Decisions: What
Are We Learning From the
Clinical Trial Data?*

*Moving to Better Biomarker
Guidance for ICI Therapies:
Current and Future Outlook*

Panel Discussion

Concluding Remarks

TARGET AUDIENCE

This activity is intended for oncologists, pulmonologists, and pathologists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Current and future role of biomarkers in guiding immune checkpoint inhibitor (ICI) treatment regimens in the management of frontline metastatic non-small cell lung cancer (NSCLC)
- Efficacy, safety, and subanalysis of data from clinical trials investigating the use of ICI treatment regimens in frontline metastatic NSCLC

Have greater competence related to

- Selecting the optimal frontline ICI treatment regimen option for patients with metastatic NSCLC

Demonstrate greater confidence in their ability to

- Use biomarkers to predict treatment response to ICI treatment regimens in clinical practice

ACCREDITATION STATEMENT

Medscape



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

FOR PHYSICIANS

Medscape, LLC designates this live activity for a maximum of **1.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.



www.medscape.org/symposium/nsclc-biomarkers-registration